Plain-English translation of NCT06585384 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage safety study testing a new combination approach for Alzheimer's disease. Researchers will give participants a medication called etanercept along with repeated specialized ultrasound scans of the brain. The goal is to see whether this combination approach is safe and whether it might help reduce some of the brain damage associated with Alzheimer's.
Currently, there are no treatments that can slow down or stop Alzheimer's disease — only medications that temporarily help with symptoms. This study is exploring a new strategy: using ultrasound to help the medication cross the protective barrier around the brain more effectively, which might give it a better chance of reducing the harmful protein buildup that damages brain cells.
You likely qualify if…
You likely don't qualify if…
Over the course of the study, participants will receive injections of the medication and undergo repeated specialized ultrasound procedures that target the brain. The exact duration and number of visits is not detailed in this record, but as a Phase I safety study with only 5 participants, it is likely to involve several visits and careful monitoring. You will have brain imaging scans (MRI) and thinking tests to make sure the treatment is safe and is not causing harm.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
France